


Case: CT2749 US - NP
USSN 10/719,188

What is claimed is:

1. (Currently Amended) A compound of Formula I or a pharmaceutically acceptable salt thereof

5



wherein

R¹ is selected from the group consisting of pyridinyl, 3-quinoliny, 2-thienyl, C₃₋₆ cycloalkyl and phenyl optionally substituted with a substituent

10 independently selected from the group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethyl and trifluoromethoxy;

A is -CH=CH- or -(CH₂)_n-;

R² is C₁₋₄ alkyl, CF₃ or hydroxymethyl;


R³, R⁴, R⁵ and R⁶ each are independently hydrogen or fluoro;

15 n is an integer of 1 or 2; and

B is 2-pyridinyl, 3-pyridinyl or 4-pyridinyl.

2. (Currently Amended) The compound of claim 1 having the Formula II or a pharmaceutically acceptable salt thereof

20



wherein

R¹ is selected from the group consisting of pyridinyl, 3-quinoliny, 2-thienyl,

C₃₋₆ cycloalkyl and phenyl optionally substituted with a substituent

25 independently selected from the group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethyl and trifluoromethoxy;

Case: CT2749 US - NP
USSN 10/719,188

A is $-\text{CH}=\text{CH}-$ or $-(\text{CH}_2)_n-$;
 R^2 is methyl or hydroxymethyl;
 R^3 , R^4 , R^5 and R^6 each are independently hydrogen or fluoro;
n is an integer of 1 or 2; and
5 B is 2-pyridinyl, 3-pyridinyl or 4-pyridinyl.

3. (Original) The compound of claim 1 selected from the group consisting of:
 (S) -3-phenyl-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;
10 (S) -3-(2-fluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;
 (S) -3-(3-fluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;
 (S) -3-(2,3-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-15 ethyl}-acrylamide;
 (S) -3-(2,4-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;
 (S) -3-(2,5-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;
20 (S) -3-(2,6-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;
 (S) -3-(3,4-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;
25 (S) -3-(3,5-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acrylamide;
 (S) -3-(2,4-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-propionamide;
 (S) -3-(3,4-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-propionamide;
30 (S) -2-(2,5-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acetamide;
 (S) -2-(2,6-difluoro-phenyl)-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acetamide;

Case: CT2749 US - NP
USSN 10/719,188

(S)-2-cyclopentyl-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acetamide; and

(S)-2-cyclohexyl-N-{1-[3-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-ethyl}-acetamide;

5 or a pharmaceutically acceptable salt thereof.

4. (Currently Amended) A pharmaceutical composition for the treatment of disorders responsive to opening of KCNQ potassium channels comprising a therapeutically effective amount of the compound of claim 1 in association with a 10 pharmaceutically acceptable carrier, adjuvant or diluent.

5. (Cancelled)

6. (Currently Amended) The method of claim 5 A method for the treatment
15 of disorders responsive to opening of the KCNQ potassium channels in a
mammal in need thereof, wherein said disorders are acute and chronic pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety and depression and neurodegenerative disorders, which comprises
administering to said mammal a therapeutically effective amount of the
20 compound of claim 1.

7. (Original) The method of claim 6 wherein said disorder is migraine.

8. (Original) The method of claim 6 wherein said disorder is neuropathic
25 pain.